MedTrace Logo

Simvastatin For Intracerebral Hemorrhage Study

NCT00718328 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-10-09

Study results available
· View outcomes & findings →

Summary

Study Objective: To analyze if statins are effective in ameliorating perihematomal edema evolution thereby reducing mortality and improving functional outcomes following spontaneous intracerebral hemorrhage (ICH).

Conditions

  • Intracerebral Hemorrhage

Interventions

DRUG

Simvastatin 80 mg

Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.

DRUG

Placebo

Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.

Sponsors & Collaborators

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • Johns Hopkins University

    lead OTHER

Principal Investigators

  • Neeraj S Naval, M.D. · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00718328 on ClinicalTrials.gov